SCHEDULE: Armistice Capital Discloses 5.39% Stake in Avanos Medical

Armistice Capital, LLC and Steven Boyd have reported a 5.39% beneficial ownership stake in Avanos Medical, Inc., totaling 2,500,000 shares of common stock.

Summary

• Armistice Capital, LLC and Steven Boyd (collectively, the "Reporting Persons") have filed a Schedule 13G regarding their beneficial ownership in AVANOS MEDICAL, INC.
• The Reporting Persons beneficially own 2,500,000 shares of Common Stock, representing 5.39% of the class.
• This percentage is based on 46,418,907 shares outstanding as of October 29, 2025, as reported in the Issuer's 10-Q filed on November 5, 2025.
• Armistice Capital, LLC, as the investment manager of Armistice Capital Master Fund Ltd., exercises shared voting and dispositive power over all 2,500,000 shares.
• Steven Boyd, as the managing member of Armistice Capital, LLC, is also deemed to beneficially own these securities.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: Neutral, as this is a mandatory ownership disclosure filing (Schedule 13G) and does not contain performance or strategic updates. The disclosure of a significant stake by an institutional investor is a factual event.

Positives

• Armistice Capital, LLC and Steven Boyd have disclosed a significant beneficial ownership stake of 5.39% in Avanos Medical, Inc., signaling institutional interest.

Future Outlook

No future outlook or guidance is provided in this beneficial ownership disclosure filing.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This filing is a standard disclosure of a significant ownership stake by an institutional investor and does not provide specific industry context or analysis.

Related Party Transactions

• Armistice Capital Master Fund Ltd., a Cayman Islands exempted company and an investment advisory client of Armistice Capital, has the right to receive dividends from, or the proceeds from the sale of, the reported securities. Armistice Capital, LLC acts as the investment manager for the Master Fund, and Steven Boyd is the managing member of Armistice Capital, LLC.

Stakeholder Impact

• The disclosure of a new 5.39% institutional stake by Armistice Capital and Steven Boyd could positively influence investor sentiment regarding Avanos Medical, Inc., signaling confidence from a notable investment firm.

Key Dates

Keywords

AVANOS MEDICAL, Armistice Capital, Steven Boyd, Schedule 13G, beneficial ownership, common stock, institutional investment